Cargando…

Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017

AIM: To describe population‐level time trends in prescribing patterns of type 2 diabetes therapy, and in short‐term clinical outcomes (glycated haemoglobin [HbA1c], weight, blood pressure, hypoglycaemia and treatment discontinuation) after initiating new therapy. MATERIALS AND METHODS: We studied 81...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dennis, John M., Henley, William E., McGovern, Andrew P., Farmer, Andrew J., Sattar, Naveed, Holman, Rury R., Pearson, Ewan R., Hattersley, Andrew T., Shields, Beverley M., Jones, Angus G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618851/ https://www.ncbi.nlm.nih.gov/pubmed/30828962 http://dx.doi.org/10.1111/dom.13687

Ejemplares similares

TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol
por: Angwin, Catherine, et al.
Publicado: (2020)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Patient stratification for determining optimal second and third line therapy for type 2 diabetes: the TriMaster study
por: Shields, Beverley M, et al.
Publicado: (2023)

Patient preference for second and third line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study
por: Shields, Beverley M, et al.
Publicado: (2023)

What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
por: McGovern, Andrew P., et al.
Publicado: (2019)

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study
por: Donnelly, Louise A., et al.
Publicado: (2020)

Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach
por: Dennis, John M, et al.
Publicado: (2018)

Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?
por: Jones, Angus G., et al.
Publicado: (2016)

Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017
por: Curtis, Helen J., et al.
Publicado: (2018)

A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin
por: Shepherd, Maggie H., et al.
Publicado: (2018)

Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data
por: Dennis, John M, et al.
Publicado: (2019)

The impact of population-level HbA(1c) screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis
por: Young, Katherine G., et al.
Publicado: (2022)

Correction to: The impact of population-level HbA(1c) screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis
por: Young, Katherine G., et al.
Publicado: (2023)

Identifying routine clinical predictors of non‐adherence to second‐line therapies in type 2 diabetes: A retrospective cohort analysis in a large primary care database
por: Shields, Beverley M., et al.
Publicado: (2019)

Identifying Good Responders to Glucose Lowering Therapy in Type 2 Diabetes: Implications for Stratified Medicine
por: Jones, Angus G., et al.
Publicado: (2014)

Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18–50 years
por: Lynam, Anita, et al.
Publicado: (2019)

Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes
por: Rodgers, Lauren R, et al.
Publicado: (2017)

Prior event rate ratio adjustment produced estimates consistent with randomized trial: a diabetes case study
por: Rodgers, Lauren R., et al.
Publicado: (2020)

Response to Comment on: Besser et al. Lessons From the Mixed-Meal Tolerance Test: Use of 90-Minute and Fasting C-Peptide in Pediatric Diabetes. Diabetes Care 2013;36:195–201
por: Shields, Beverley M., et al.
Publicado: (2013)

Patient‐led rapid titration of basal insulin in gestational diabetes is associated with improved glycaemic control and lower birthweight
por: McGovern, Andrew P., et al.
Publicado: (2022)

Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning
por: Dakin, Helen A., et al.
Publicado: (2020)

Glycaemic Effects of Non-statin Lipid-Lowering Therapies
por: Collins, Patrick D., et al.
Publicado: (2016)

Initiating Insulin as Part of the Treating To Target in Type 2 Diabetes (4-T) Trial: An interview study of patients' and health professionals' experiences
por: Jenkins, Nicholas, et al.
Publicado: (2010)

Unravelling the Heterogeneity of Non Insulin Dependent Diabetes
por: Pearson, Ewan R, et al.
Publicado: (2000)

Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy
por: Young, Katherine G., et al.
Publicado: (2023)

Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine
por: Venkatasubramaniam, Ashwini, et al.
Publicado: (2023)

Challenges of maintaining research protocol fidelity in a clinical care setting: A qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial
por: Lawton, Julia, et al.
Publicado: (2011)

Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis
por: Whyte, Martin B., et al.
Publicado: (2019)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation
por: McGovern, Andrew P., et al.
Publicado: (2021)

Strategies to identify individuals with monogenic diabetes: results of an economic evaluation
por: Peters, Jaime L, et al.
Publicado: (2020)

Antibiotic prescribing in Danish general practice in the elderly population from 2010 to 2017
por: Veimer Jensen, Maria Louise, et al.
Publicado: (2021)

Maternal hypothyroxinaemia in pregnancy is associated with obesity and adverse maternal metabolic parameters
por: Knight, Bridget A, et al.
Publicado: (2016)

Assessment of the HNF1B Score as a Tool to Select Patients for HNF1B Genetic Testing
por: Clissold, Rhian, et al.
Publicado: (2015)

The effect of a brief action planning intervention on adherence to double-blind study medication compared to a standard trial protocol in the Atorvastatin in Factorial with Omega EE90 Risk Reduction in Diabetes (AFORRD) clinical trial: a cluster randomised sub-study
por: Farmer, Andrew J., et al.
Publicado: (2016)

The SSRI Clinic: Improving SSRI Prescribing Safety in Outpatient CAMHS Clinic
por: Morgan, Tammy, et al.
Publicado: (2022)

Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study
por: Rodgers, Lauren R., et al.
Publicado: (2021)

Associations between low HDL, sex and cardiovascular risk markers are substantially different in sub-Saharan Africa and the UK: analysis of four population studies
por: Greiner, Rosamund, et al.
Publicado: (2021)

Rates of glycaemic deterioration in a real-world population with type 2 diabetes
por: Donnelly, Louise A., et al.
Publicado: (2017)

REAL-WORLD EFFECTIVENESS ENHANCED INFLUENZA VACCINES IN OLDER ADULTS DURING THREE CONSECUTIVE INFLUENZA SEASONS: 2017–2020
por: McGovern, Ian
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n6e4sph7jlpcd7hvcuam7rgqmc